glp 1 for chronic kidney disease GLP-1 Receptor Agonists and Protection SGLT2 vs GLP-1 for CKD:

A 2022 meta-analysis found green tea polyphenols may improve insulin sensitivity and fasting glucose, but did not measure GLP-1 directly

Many people find the abdomen easiest for self-injection

PlexusDx eliminates insurance requirements entirely

Greater adherence to these drugs, such as Wegovy, which make you feel fuller faster and longer, is associated with greater weight loss

Antiinflammatory actions of glucagon-like peptide-1based therapies beyond metabolic benefits Text PDF Abstract Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders